Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2023 |TAVR in Cardiogenic Shock

Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear.

The aim of this study was to assess events in patients undergoing TAVR with balloon expandable valves (SAPIEN 3 and SAPIEN 3 Ultra). 

Populations were matched with propensity score. Primary end point was inhospital all-cause mortality, at 30 days and one year, and major complications in the same period of time. 

Data from 4952 patients with cardiogenic shock were obtained. Mean age was 75.6 year with mean ejection fraction of 39.9%. observed complications were annulus rupture in 0.3%, aortic dissection in 0.2%, 0.4% coronary obstruction, 1% cardiac perforation, 0.2% devise embolization and 0.7% conversion to open surgery. 

Compared against the matched cohort with no cardiogenic shock, there was more inhospital mortality (9.9% vs 2.7%, P<0.0001), stroke (2.9% vs 1.5%; P<0.0001), vascular complications (2.3% vs 1.3%, P<0.0001) and major bleeding (2.5% vs 0.7%, P<0.0001). 

At one year, were was 29.7% mortality vs 22.6% in patients with no cardiogenic shock (HR 1.57, CI 95% 1.43-1.72, P<0.001). After multivariable analysis, predictors of mortality at 30 days were dialysis, pacemaker implantation, assisting device requirement, and peripheral vascular disease. 

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

The author concluded that TAVR was effective and safe in the context of cardiogenic shock with acceptable events at 30 days and one year. These outcomes observed in a registry should suggest “primary” TAVR as the best strategy for patients with aortic stenosis leading to cardiogenic shock. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Abhijeet Dhoble at Late Breaking Trials Sessions, EuroPCR 2023, May 16, 2023, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....